Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-105016
Filing Date
2024-09-10
Accepted
2024-09-10 13:26:57
Documents
80
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q emma-20240630.htm   iXBRL 10-Q 2586350
2 EX-10.1 emma-ex10_1.htm EX-10.1 382146
3 EX-31.1 emma-ex31_1.htm EX-31.1 11421
4 EX-31.2 emma-ex31_2.htm EX-31.2 11510
5 EX-32.1 emma-ex32_1.htm EX-32.1 9746
6 GRAPHIC img109337448_0.jpg GRAPHIC 9477
7 GRAPHIC img109337448_1.jpg GRAPHIC 9477
8 GRAPHIC img109337448_2.jpg GRAPHIC 7943
9 GRAPHIC img109337448_3.jpg GRAPHIC 1112
10 GRAPHIC img109337448_4.jpg GRAPHIC 3679
11 GRAPHIC img109337448_5.jpg GRAPHIC 707
12 GRAPHIC img109337448_6.jpg GRAPHIC 3039
  Complete submission text file 0000950170-24-105016.txt   13913558

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT emma-20240630.xsd EX-101.SCH 1736041
82 EXTRACTED XBRL INSTANCE DOCUMENT emma-20240630_htm.xml XML 3264848
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35527 | Film No.: 241289590
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)